No blood clot reports; less than 1% of people had side effects from COVID-19 vaccines in PH

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

FILE PHOTO

Metro Manila (CNN Philippines, June 18) — Less than one percent of people who received COVID-19 vaccines in the country as of June 6 had suspected side effects, most of them mild, the Department of Health said Friday.

Of the nearly six million who got vaccinated against the coronavirus, 0.68% reported they experienced side effects, the DOH said. "All were given appropriate care," the department said.

Of the suspected reactions to COVID-19 shots, 98% are considered non-serious, while 1.89% were tagged as serious, the department said. The common side effects include chills, fatigue, fever, nausea, and pain on the injection site, Department of Health Undersecretary Maria Rosario Vergeire said in a media forum.

So far, no causal links between COVID-19 vaccines and adverse events have been established, she added.

No blood clots after AstraZeneca vaccinations

Meanwhile, in the Philippines, none developed blood clots after getting AstraZeneca's COVID-19 vaccine, Vergeire said.

The country is allowing the use of AstraZeneca shots for people aged 18 and up.

"Dito sa atin wala pa po tayong nakikitang ganitong adverse event," she said.

[Translation: We have not yet recorded this type of adverse event.]

Vergeire's statement came a day after Australian authorities recommended that AstraZeneca shots be limited to people over 60 years old. The recommendation was made after they recorded cases of rare blood clots linked to the AstraZeneca vaccine, with the higher rates of this condition seen in individuals aged 50 to 59.

But Australian officials said people of all ages who had their first dose of the AstraZeneca shot but did not experience serious side effects should still get their second dose of the same brand.

They noted the benefits of vaccination with any vaccine, including AstraZeneca, outweigh the risks of blood clots.

Vergeire shared the same view.